Overview

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Status:
Completed
Trial end date:
2020-12-24
Target enrollment:
Participant gender:
Summary
CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Rituximab